标题
New approaches to symptomatic treatments for Alzheimer’s disease
作者
关键词
-
出版物
Molecular Neurodegeneration
Volume 16, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-01-13
DOI
10.1186/s13024-021-00424-9
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial
- (2020) W. Joseph Herring et al. Alzheimers & Dementia
- Lemborexant: First Approval
- (2020) Lesley J. Scott DRUGS
- The Neuropsychiatric Inventory: Development and Applications
- (2020) Jeffrey Cummings JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY
- Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia
- (2020) Shorena Janelidze et al. NATURE MEDICINE
- Distinct Symptom-Specific Treatment Targets for Circuit-Based Neuromodulation
- (2020) Shan H. Siddiqi et al. AMERICAN JOURNAL OF PSYCHIATRY
- A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia
- (2020) Kenneth S. Koblan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Use of Run-in Periods in Randomized Trials
- (2020) Xiqian Huo et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of Rotigotine vs Placebo on Cognitive Functions Among Patients With Mild to Moderate Alzheimer Disease
- (2020) Giacomo Koch et al. JAMA Network Open
- Drug Development for Psychotropic, Cognitive-Enhancing, and Disease-Modifying Treatments for Alzheimer’s Disease
- (2020) Jeffrey Cummings JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES
- The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans
- (2019) Jerrah K. Holth et al. SCIENCE
- The Alzheimer’s Disease Clinical Spectrum
- (2019) Alireza Atri MEDICAL CLINICS OF NORTH AMERICA
- Novel pathways in the treatment of Major Depression: focus on the glutamatergic system
- (2019) Carmine Tomasetti et al. CURRENT PHARMACEUTICAL DESIGN
- Randomized placebo controlled trial of nabilone for agitation in Alzheimer's disease
- (2019) Nathan Herrmann et al. AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
- Effect of phosphodiesterase (1B, 2A, 9A and 10A) inhibitors on central nervous system cyclic nucleotide levels of rats and mice
- (2019) Jie Chen et al. NEUROCHEMISTRY INTERNATIONAL
- Targeting opioid dysregulation in depression for the development of novel therapeutics
- (2019) Caroline A. Browne et al. PHARMACOLOGY & THERAPEUTICS
- Randomized clinical trials with run-in periods: frequency, characteristics and reporting
- (2019) David Ruben Teindl Laursen et al. Clinical Epidemiology
- Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression
- (2019) Xinyi Wang et al. CELL RESEARCH
- Bidirectional relationship between sleep and Alzheimer’s disease: role of amyloid, tau, and other factors
- (2019) Chanung Wang et al. NEUROPSYCHOPHARMACOLOGY
- The “rights” of precision drug development for Alzheimer’s disease
- (2019) Jeffrey Cummings et al. Alzheimers Research & Therapy
- Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials
- (2019) George T. Grossberg et al. AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
- Alzheimer's disease and sleep disturbances: a review
- (2019) Conrado Regis Borges et al. ARQUIVOS DE NEURO-PSIQUIATRIA
- Antipsychotic-like effects of a novel phosphodiesterase 10A inhibitor T-251 in rodents
- (2019) Misae Takakuwa et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- Revisiting Criteria for Psychosis in Alzheimer’s Disease and Related Dementias: Toward Better Phenotypic Classification and Biomarker Research
- (2019) Corinne E. Fischer et al. JOURNAL OF ALZHEIMERS DISEASE
- The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
- (2018) Harald Hampel et al. BRAIN
- Cognitive correlates of α4β2 nicotinic acetylcholine receptors in mild Alzheimer’s dementia
- (2018) Osama Sabri et al. BRAIN
- The role of 5 HT6-receptor antagonists in Alzheimer’s disease: an update
- (2018) Rita Khoury et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- A novel GLP-1/GIP/Gcg triagonist reduces cognitive deficits and pathology in the 3xTg mouse model of Alzheimer's disease
- (2018) Tian Li et al. HIPPOCAMPUS
- Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease
- (2018) Alireza Atri et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Muscarinic and nicotinic acetylcholine receptor agonists: current scenario in Alzheimer's disease therapy
- (2018) Stuti Verma et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study
- (2018) Clive Ballard et al. LANCET NEUROLOGY
- The Gut Microbiome Alterations and Inflammation-Driven Pathogenesis of Alzheimer’s Disease—a Critical Review
- (2018) Marta Sochocka et al. MOLECULAR NEUROBIOLOGY
- High performance plasma amyloid-β biomarkers for Alzheimer’s disease
- (2018) Akinori Nakamura et al. NATURE
- The Disease-modifying Drug Candidate, SAK3 Improves Cognitive Impairment and Inhibits Amyloid beta Deposition in App Knock-in Mice
- (2018) Hisanao Izumi et al. NEUROSCIENCE
- Bioenergetics and synaptic plasticity as potential targets for individualizing treatment for depression
- (2018) J. Blair Price et al. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
- The role of dopaminergic midbrain in Alzheimer’s disease: Translating basic science into clinical practice
- (2018) Marcello D’Amelio et al. PHARMACOLOGICAL RESEARCH
- The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial
- (2018) Roberta W. Scherer et al. Trials
- Exploring Data Quality Management within Clinical Trials
- (2018) Yasmine Probst et al. Applied Clinical Informatics
- Is it time to revise the diagnostic criteria for apathy in brain disorders? The 2018 international consensus group
- (2018) P. Robert et al. EUROPEAN PSYCHIATRY
- Neurobiological Correlates of Apathy in Alzheimer's Disease and Mild Cognitive Impairment: A Critical Review
- (2018) Florindo Stella et al. JOURNAL OF ALZHEIMERS DISEASE
- Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer's Disease: A Systematic Review and Meta-Analysis
- (2018) Chen-Chen Tan et al. JOURNAL OF ALZHEIMERS DISEASE
- Why Do They Just Sit? Apathy as a Core Symptom of Alzheimer Disease
- (2018) Carolyn W. Zhu et al. AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
- Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer’s disease: a network meta-analysis of 41 randomized controlled trials
- (2018) Kai-Xin Dou et al. Alzheimers Research & Therapy
- A phase I, randomized, proof-of-clinical-mechanism study assessing the pharmacokinetics and pharmacodynamics of the oral PDE9A inhibitor BI 409306 in healthy male volunteers
- (2017) Katja Boland et al. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
- New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis
- (2017) Albert Yang et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Sembragiline in Moderate Alzheimer’s Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD)
- (2017) Stephane Nave et al. JOURNAL OF ALZHEIMERS DISEASE
- Efficacy of Antidepressants for Depression in Alzheimer’s Disease: Systematic Review and Meta-Analysis
- (2017) Vasiliki Orgeta et al. JOURNAL OF ALZHEIMERS DISEASE
- Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer’s Disease
- (2017) Thomas N. Chase et al. Neurotherapeutics
- Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials
- (2016) Jeff Sevigny et al. ALZHEIMER DISEASE & ASSOCIATED DISORDERS
- The flavonoid baicalein rescues synaptic plasticity and memory deficits in a mouse model of Alzheimer’s disease
- (2016) Xun-Hu Gu et al. BEHAVIOURAL BRAIN RESEARCH
- Neuropsychiatric Disturbances in Alzheimer's Disease: What Have We Learned from Neuropathological Studies?
- (2016) Debby Van Dam et al. Current Alzheimer Research
- The prevalence of neuropsychiatric symptoms in Alzheimer's disease: Systematic review and meta-analysis
- (2016) Qing-Fei Zhao et al. JOURNAL OF AFFECTIVE DISORDERS
- Cognitive-Enhancing Effects of a Polyphenols-Rich Extract from Fruits without Changes in Neuropathology in an Animal Model of Alzheimer’s Disease
- (2016) Alexandre Dal-Pan et al. JOURNAL OF ALZHEIMERS DISEASE
- ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials
- (2016) Jinping Wang et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Alzheimer's disease
- (2016) Philip Scheltens et al. LANCET
- Noradrenergic System in Down Syndrome and Alzheimer's Disease A Target for Therapy
- (2015) Cristy Phillips et al. Current Alzheimer Research
- Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review
- (2015) Joshua D. Rosenblat et al. Current Neuropharmacology
- Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial
- (2015) Paul B. Rosenberg et al. INTERNATIONAL PSYCHOGERIATRICS
- Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia
- (2015) Jeffrey L. Cummings et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Neuroinflammation in Alzheimer's disease
- (2015) Michael T Heneka et al. LANCET NEUROLOGY
- Sleep and Alzheimer's disease
- (2015) Laure Peter-Derex et al. SLEEP MEDICINE REVIEWS
- Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: a pooled area under the curve analysis
- (2015) Alireza Atri et al. Alzheimers Research & Therapy
- Alzheimer's disease
- (2015) Colin L. Masters et al. Nature Reviews Disease Primers
- Efficacy and safety evaluation of HSD-1 inhibitor ABT-384 in Alzheimer's disease
- (2014) Gerard J. Marek et al. Alzheimers & Dementia
- Computerized Cognitive Testing for Older Adults
- (2014) Stelios Zygouris et al. American Journal of Alzheimers Disease and Other Dementias
- Phosphodiesterase Inhibitors as a Target for Cognition Enhancement in Aging and Alzheimer’s Disease: A Translational Overview
- (2014) P.R.A. Heckman et al. CURRENT PHARMACEUTICAL DESIGN
- Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition
- (2014) Jeffrey Cummings et al. INTERNATIONAL PSYCHOGERIATRICS
- Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
- (2014) Jeffrey L Cummings et al. Alzheimers Research & Therapy
- Psychosis in Alzheimer’s Disease is Associated with Frontal Metabolic Impairment and Accelerated Decline in Working Memory: Findings from the Alzheimer's Disease Neuroimaging Initiative
- (2013) Jeremy Koppel et al. AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
- Safety and Efficacy of Methylphenidate for Apathy in Alzheimer’s Disease
- (2013) Paul B. Rosenberg et al. JOURNAL OF CLINICAL PSYCHIATRY
- Cholinergic circuitry of the human nucleus basalis and its fate in Alzheimer's disease
- (2013) M.-Marsel Mesulam JOURNAL OF COMPARATIVE NEUROLOGY
- Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial
- (2013) Jeffrey Cummings et al. LANCET
- Sleep and Alzheimer disease pathology—a bidirectional relationship
- (2013) Yo-El S. Ju et al. Nature Reviews Neurology
- Progress in novel cognitive enhancers for cognitive aging and Alzheimer’s disease
- (2013) Diana W Shineman et al. Alzheimers Research & Therapy
- Neurotoxicity of Amyloid -Protein: Synaptic and Network Dysfunction
- (2013) L. Mucke et al. Cold Spring Harbor Perspectives in Medicine
- Increasing trial efficiency by early reallocation of placebo nonresponders in sequential parallel comparison designs: Application to antidepressant trials
- (2012) Ruud Boessen et al. Clinical Trials
- Relapse Risk after Discontinuation of Risperidone in Alzheimer's Disease
- (2012) D.P. Devanand et al. NEW ENGLAND JOURNAL OF MEDICINE
- The placebo response in clinical trials: more questions than answers
- (2011) P. Enck et al. PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
- A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease
- (2010) D.P. Devanand et al. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY
- Neurochemical basis for symptomatic treatment of Alzheimer's disease
- (2010) Paul T. Francis et al. NEUROPHARMACOLOGY
- Prazosin for the Treatment of Behavioral Symptoms in Patients With Alzheimer Disease With Agitation and Aggression
- (2009) Lucy Y. Wang et al. AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
- Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine
- (2009) Joanne Rodda et al. INTERNATIONAL PSYCHOGERIATRICS
- M1 Muscarinic Agonists Target Major Hallmarks of Alzheimer’s Disease – The Pivotal Role of Brain M1 Receptors
- (2008) Abraham Fisher Neurodegenerative Diseases
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started